These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 32142770)

  • 1. Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity.
    Mehrpouri M; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Momeny M; Bashash D
    Eur J Pharmacol; 2020 May; 875():173050. PubMed ID: 32142770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abrogation of histone deacetylases (HDACs) decreases survival of chronic myeloid leukemia cells: New insight into attenuating effects of the PI3K/c-Myc axis on panobinostat cytotoxicity.
    Zehtabcheh S; Yousefi AM; Salari S; Safa M; Momeny M; Ghaffari SH; Bashash D
    Cell Biol Int; 2021 May; 45(5):1111-1121. PubMed ID: 33501756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic effects of BKM120 and panobinostat on pre-B acute lymphoblastic cells: an emerging perspective for the simultaneous inhibition of PI3K and HDACs.
    Mehrpouri M; Momeny M; Bashash D
    J Recept Signal Transduct Res; 2022 Feb; 42(1):100-108. PubMed ID: 33969806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines.
    Bandolik JJ; Hamacher A; Schrenk C; Weishaupt R; Kassack MU
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234549
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-HDAC inhibitor panobinostat, as a single agent or in combination with PI3K inhibitor, induces apoptosis in APL cells: An emerging approach to overcome MSC-induced resistance.
    Mosleh M; Safaroghli-Azar A; Bashash D
    Int J Biochem Cell Biol; 2020 May; 122():105734. PubMed ID: 32119989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-Myc inhibition sensitizes pre-B ALL cells to the anti-tumor effect of vincristine by altering apoptosis and autophagy: Proposing a probable mechanism of action for 10058-F4.
    Sheikh-Zeineddini N; Safaroghli-Azar A; Salari S; Bashash D
    Eur J Pharmacol; 2020 Mar; 870():172821. PubMed ID: 31770526
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression of c-Myc using 10058-F4 exerts caspase-3-dependent apoptosis and intensifies the antileukemic effect of vincristine in pre-B acute lymphoblastic leukemia cells.
    Sheikh-Zeineddini N; Bashash D; Safaroghli-Azar A; Riyahi N; Shabestari RM; Janzamin E; Safa M
    J Cell Biochem; 2019 Aug; 120(8):14004-14016. PubMed ID: 30957273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.
    Buontempo F; Orsini E; Lonetti A; Cappellini A; Chiarini F; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; Bertacchini J; Neri LM; McCubrey JA; Martelli AM
    Oncotarget; 2016 Jan; 7(2):1323-40. PubMed ID: 26593250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and Bim.
    Dai Y; Chen S; Wang L; Pei XY; Kramer LB; Dent P; Grant S
    Br J Haematol; 2011 Apr; 153(2):222-35. PubMed ID: 21375523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB.
    Bastian L; Hof J; Pfau M; Fichtner I; Eckert C; Henze G; Prada J; von Stackelberg A; Seeger K; Shalapour S
    Clin Cancer Res; 2013 Mar; 19(6):1445-57. PubMed ID: 23357978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histone Deacetylase Inhibitors as Anticancer Drugs.
    Eckschlager T; Plch J; Stiborova M; Hrabeta J
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ergolide, a potent sesquiterpene lactone induces cell cycle arrest along with ROS-dependent apoptosis and potentiates vincristine cytotoxicity in ALL cell lines.
    Yami A; Hamzeloo-Moghadam M; Darbandi A; Karami A; Mashati P; Takhviji V; Gharehbaghian A
    J Ethnopharmacol; 2020 May; 253():112504. PubMed ID: 31904493
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis.
    Garrido Castro P; van Roon EHJ; Pinhanços SS; Trentin L; Schneider P; Kerstjens M; Te Kronnie G; Heidenreich O; Pieters R; Stam RW
    Leukemia; 2018 Feb; 32(2):323-331. PubMed ID: 28690313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indole-3-carbinol suppresses NF-κB activity and stimulates the p53 pathway in pre-B acute lymphoblastic leukemia cells.
    Safa M; Tavasoli B; Manafi R; Kiani F; Kashiri M; Ebrahimi S; Kazemi A
    Tumour Biol; 2015 May; 36(5):3919-30. PubMed ID: 25589462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
    Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
    PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
    Rao R; Balusu R; Fiskus W; Mudunuru U; Venkannagari S; Chauhan L; Smith JE; Hembruff SL; Ha K; Atadja P; Bhalla KN
    Mol Cancer Ther; 2012 Apr; 11(4):973-83. PubMed ID: 22367781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SIRT1 activation enhances HDAC inhibition-mediated upregulation of GADD45G by repressing the binding of NF-κB/STAT3 complex to its promoter in malignant lymphoid cells.
    Scuto A; Kirschbaum M; Buettner R; Kujawski M; Cermak JM; Atadja P; Jove R
    Cell Death Dis; 2013 May; 4(5):e635. PubMed ID: 23681230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia.
    Waibel M; Vervoort SJ; Kong IY; Heinzel S; Ramsbottom KM; Martin BP; Hawkins ED; Johnstone RW
    Leukemia; 2018 Jan; 32(1):237-241. PubMed ID: 28914259
    [No Abstract]   [Full Text] [Related]  

  • 19. Krüppel-like factor 9 and histone deacetylase inhibitors synergistically induce cell death in glioblastoma stem-like cells.
    Tung B; Ma D; Wang S; Oyinlade O; Laterra J; Ying M; Lv SQ; Wei S; Xia S
    BMC Cancer; 2018 Oct; 18(1):1025. PubMed ID: 30348136
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.
    Mondello P; Brea EJ; De Stanchina E; Toska E; Chang AY; Fennell M; Seshan V; Garippa R; Scheinberg DA; Baselga J; Wendel HG; Younes A
    JCI Insight; 2017 Mar; 2(6):e90196. PubMed ID: 28352655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.